Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. monthly Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E17.12 EPS (ttm)17.41 Insider Own19.40% Shs Outstand108.48M Perf Week-2.44%
Market Cap32.33B Forward P/E11.87 EPS next Y25.11 Insider Trans-0.05% Shs Float80.11M Perf Month0.72%
Income2.00B PEG2.99 EPS next Q6.33 Inst Own73.90% Short Float2.83% Perf Quarter-3.64%
Sales7.24B P/S4.47 EPS this Y57.40% Inst Trans-0.04% Short Ratio3.21 Perf Half Y-13.41%
Book/sh89.34 P/B3.34 EPS next Y7.47% ROA17.00% Target Price382.68 Perf Year-24.60%
Cash/sh24.61 P/C12.11 EPS next 5Y5.72% ROE23.10% 52W Range271.37 - 442.00 Perf YTD-20.22%
Dividend- P/FCF16.96 EPS past 5Y40.30% ROI24.90% 52W High-32.58% Beta1.12
Dividend %- Quick Ratio3.30 Sales past 5Y26.10% Gross Margin93.40% 52W Low9.81% ATR7.12
Employees7400 Current Ratio3.90 Sales Q/Q20.30% Oper. Margin29.60% RSI (14)55.90 Volatility1.59% 2.57%
OptionableYes Debt/Eq0.07 EPS Q/Q-65.00% Profit Margin28.60% Rel Volume0.70 Prev Close300.19
ShortableYes LT Debt/Eq0.07 EarningsNov 05 BMO Payout0.00% Avg Volume707.11K Price297.99
Recom2.40 SMA202.99% SMA502.82% SMA200-12.83% Volume496,772 Change-0.73%
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Oct-18-19 08:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Oct-14-19 11:46AM  3 Undervalued Stocks to Buy According to Goldman Sachs InvestorPlace
Oct-11-19 04:27PM  Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off Investor's Business Daily
Oct-10-19 06:22PM  Hedge Funds Have Never Been This Bullish On Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
10:11AM  Wet AMD Space in Focus: New Drug Approvals & Key Advancements Zacks
09:57AM  Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study Zacks
09:30AM  Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019 PR Newswire
Oct-09-19 12:07PM  New Novartis Drug Tabbed as Blockbuster
11:10AM  Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval Zacks
Oct-08-19 04:10PM  Can This Pharma Giant Undercut Regeneron's Biggest Moneymaker? Investor's Business Daily
Oct-03-19 03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
Oct-01-19 10:23AM  Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Excessively Paying Its CEO? Simply Wall St.
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
10:46AM  Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study Zacks
Sep-29-19 09:15PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 27
Sep-26-19 11:59AM  Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late Zacks
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 04:19PM  Why Investors Are Beginning To Doubt This Biotech's R&D Prowess Investor's Business Daily
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
11:13AM  The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron Zacks
10:54AM  Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts Say
Sep-20-19 02:14PM  Top Research Reports for Target, Illumina & T-Mobile US Zacks
07:50AM  Regeneron Rises After European Committee Adopts Positive Opinion on Dupixent
06:59AM  The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) PR Newswire
06:44AM  CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire
Sep-19-19 11:02AM  Alnylam Focuses on Pipeline Development Amid Competition Zacks
Sep-18-19 06:59AM  Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis PR Newswire
Sep-17-19 10:27AM  Alnylam Begins Phase III Study on Onpattro for New Indication Zacks
07:00AM  Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies PR Newswire
Sep-16-19 01:18PM  Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Zacks
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-13-19 10:08AM  Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Zacks
10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-11-19 06:01AM  Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe Zacks
Sep-08-19 05:09PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 6
Sep-05-19 09:31AM  Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound? Zacks
Sep-04-19 10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
Aug-30-19 10:26AM  Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
06:30AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
Aug-29-19 09:16AM  Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court Zacks
07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga
Aug-28-19 04:56PM  U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 PR Newswire
04:18PM  U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
03:41PM  UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
03:18PM  U.S. judge rules for Sanofi in Amgen patent fight Reuters
10:43AM  Amgen Faces Trouble in the Anti-Cholesterol-Drug Battle, Analyst Says
Aug-27-19 06:00AM  The region's largest construction project is taking shape on Regeneron's campus American City Business Journals
Aug-26-19 04:49PM  Inovio (INO) Down More Than 30% in 3 Months: Here's Why Zacks
11:05AM  Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
09:49AM  Read This Before You Buy Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Because Of Its P/E Ratio Simply Wall St.
Aug-22-19 01:26PM  Bill Nygren Drills Into Permian Basin Oil
11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
Aug-21-19 12:05PM  The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier Zacks
11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 05:14PM  Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Zacks
04:46PM  Here's Why AnaptysBio Shares Are Slipping Today Motley Fool
02:28PM  Top Analyst Reports for Estee Lauder, Becton, Dickinson & Applied Materials Zacks
01:06PM  8 Biotech Stocks to Watch After the Q2 Earnings Season InvestorPlace
Aug-15-19 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
08:28AM  Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe Zacks
Aug-14-19 12:35PM  Edited Transcript of REGN earnings conference call or presentation 6-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
09:55AM  Is Regeneron Pharmaceuticals (REGN) A Great Pick for Value Investors? Zacks
09:33AM  Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial Benzinga
09:21AM  Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
07:50AM  The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering Benzinga
07:00AM  Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol PR Newswire
Aug-13-19 11:47AM  A Promising Ebola Drug Isnt Helping Regeneron Stock. Heres Why.
11:01AM  Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle Benzinga
10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
07:00AM  FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe PR Newswire
Aug-12-19 02:40PM  New experimental Ebola drugs are saving lives in Africa MarketWatch
11:17AM  UPDATE 5-Ebola "no longer incurable" as Congo trial finds drugs boost survival Reuters
10:17AM  Regeneron's Ebola treatment proves superior to rival in trial Reuters
10:14AM  Congo trial of Ebola treatments switches to focus on two drugs Reuters
10:01AM  PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths PR Newswire
Aug-10-19 07:56PM  AnaptysBio Prepares for a Potential Gear Shift Motley Fool
Aug-08-19 06:00AM  Regeneron sales grow 20% as it moves ahead with $800 million expansion in East Greenbush American City Business Journals
Aug-07-19 10:03AM  Company News for Aug 7, 2019 Zacks
08:13AM  Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates Zacks
Aug-06-19 11:25PM  Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript Motley Fool
04:21PM  This Big Biotech Stock Just Posted An Eye-Popping Earnings Beat Investor's Business Daily
03:00PM  Regeneron Pharmaceuticals Reports Marked Improvement in Q2 Motley Fool
01:09PM  Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid Zacks
08:24AM  Regeneron stock up 2.2% after earnings beat MarketWatch
08:18AM  Regeneron Pharmaceuticals Reports Q2 Earnings Beat Benzinga
07:45AM  Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates Zacks
07:06AM  UPDATE 2-Regeneron beats second-quarter profit estimates on Eylea boost Reuters
06:40AM  Regeneron second-quarter revenue beats on Eylea sales Reuters
06:30AM  Regeneron Reports Second Quarter 2019 Financial and Operating Results PR Newswire
02:40AM  Regeneron Pharma Earnings, Revenue Beat in Q2
01:40AM  UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases Reuters
01:15AM  EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases Reuters
01:04AM  Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis PR Newswire
12:59AM  Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis PR Newswire
Aug-05-19 05:59PM  Sanofi (SNY) Q2 2019 Earnings Call Transcript Motley Fool
05:09PM  Jerome Dodson's Parnassus Endeavor Fund 2nd-Quarter Commentary
05:09PM  Jerome Dodson Comments on Regeneron Pharmaceuticals
10:59AM  Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM